Speculation that Moderna, Inc.’s Spikevax windfall could lead to an interest in mergers and acquisitions has gained added substance as the company indicated during its first quarter sales and earnings call that it is looking at potential deals around the world. At the same time, while Q1 revenues beat consensus expectations, analysts are bracing for the possibility of lower revenue as the COVID-19 pandemic becomes endemic.
Moderna Teases M&A Interest As Pandemic Expected To Wind Down
Biotech Anticipates Four Phase III Programs In Clinic in Q2
Spikevax revenues beat expectations but analysts are bracing for the eventuality of lower vaccine revenues as COVID-19 becomes endemic. Moderna will have four new vaccines in Phase III this quarter.

More from Earnings
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
More from Business
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.